New Study Shows Iridex Laser Treatment Safely Lowers Eye Pressure for Glaucoma Patients

Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma.1

The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma who underwent retreatment following variable responses to their primary procedure. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment.

"These findings support retreatment with MicroPulse TLT as a valuable option in glaucoma care, particularly for patients who experienced an initial IOP-lowering benefit that diminished over time," said lead author Dr. Ronald de Crom. "The results also indicate that long-term success and repeatability is most favorable in patients who responded to the primary treatment, helping clinicians better identify candidates for retreatment."

Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition, depending on when the effect of the primary procedure began to diminish. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases. This variability demonstrates the procedure's real-world flexibility in sustaining IOP control over time.